drugset

drugset / Trial / NCT01635712

Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies

NCT01635712 ↗

Phase 1 Completed 10 enrolled Esanex Inc.

NaSingle-groupOpen-labelTreatment

Summary

Hsp90 is a chemical in the body that is involved int he promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90.

Timeline

Start: 2014-02
Primary completion: 2016-01
Completion: 2017-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SNX-5422	Small molecule	—	Oral

Indications